Stroke prophylaxis in nonvalvular atrial fibrillation<

Nonvalvular atrial fibrillation is the most prevalent dysrrhythmia, and carries with it an at least fivefold increased risk of ischaemic stroke. Currently, the implementation and optimization of prophylactic therapy (with warfarin or acetylsalicylic acid) is the most effective approach, at the population level, to optimize outcomes in patients with atrial fibrillation. Therefore, clinical trial evidence regarding warfarin and acetylsalicylic acid in stroke prophylaxis is highlighted. Recently, considerable data have emerged that indicate suboptimal use of warfarin in clinical practice (both in terms of the prescription and titration of therapy). Narrowing this gap between research evidence and clinical practice may be accomplished by identifying those patients who are eligible for prophylaxis, and then maintaining them at an adequate level of anticoagulation.

[1]  R. Sacco,et al.  Antithrombotic and thrombolytic therapy for ischemic stroke. , 2001, Chest.

[2]  R. Tsuyuki,et al.  Adequacy of Anticoagulation in Patients with Atrial Fibrillation Coming to a Hospital , 2000, Pharmacotherapy.

[3]  L. Kalra,et al.  Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness , 2000, BMJ : British Medical Journal.

[4]  D. Witter,et al.  Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. , 2000, Archives of internal medicine.

[5]  E. Berge,et al.  Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study , 2000, The Lancet.

[6]  R. Kronmal,et al.  Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses. , 2000, Archives of neurology.

[7]  J. Hirsh,et al.  Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study. , 2000, Archives of internal medicine.

[8]  F. Madoré,et al.  Oral anticoagulant therapy for heart disease: results in actual cardiology practice. , 2000, The Canadian journal of cardiology.

[9]  F. McAlister,et al.  Why do patients with atrial fibrillation not receive warfarin? , 2000, Archives of internal medicine.

[10]  Allen J. Taylor,et al.  Can Warfarin Randomized Trials Be Reproduced in ‘Real Life’?: Adherence to Warfarin Guidelines for Intensity of Anticoagulation in a University-Based Warfarin Clinic , 2000, Southern medical journal.

[11]  Taylor Aj,et al.  Can warfarin randomized trials be reproduced in 'real life'? Adherence to warfarin guidelines for intensity of anticoagulation in a university-based warfarin clinic. , 2000 .

[12]  W. Newton,et al.  Preventing stroke in patients with atrial fibrillation. , 2000, The Journal of family practice.

[13]  R. Hart,et al.  Atrial Fibrillation and Thromboembolism: A Decade of Progress in Stroke Prevention , 1999, Annals of Internal Medicine.

[14]  D. Leys,et al.  Stroke and atrial fibrillation: is stroke prevention treatment appropriate beforehand? , 1999, Heart.

[15]  Á. Chamorro,et al.  Heparin in acute stroke with atrial fibrillation: clinical relevance of very early treatment. , 1999, Archives of neurology.

[16]  David C. Anderson,et al.  ATRIAL FIBRILLATION AND STROKE: EPIDEMIOLOGY, PATHOPHYSIOLOGY, AND MANAGEMENT , 1998 .

[17]  H. Krumholz,et al.  Warfarin use among patients with atrial fibrillation. , 1997, Stroke.

[18]  S. Kemp,et al.  Clinical characteristics and management of acute stroke in patients with atrial fibrillation admitted to US university hospitals , 1997, Neurology.

[19]  Peter Sandercock,et al.  The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke , 1997, The Lancet.

[20]  J. Avorn,et al.  Atrial fibrillation and stroke prevention with warfarin in the long-term care setting. , 1997, Archives of internal medicine.

[21]  Atrial fibrillation follow-up investigation of rhythm management -- the AFFIRM study design. The Planning and Steering Committees of the AFFIRM study for the NHLBI AFFIRM investigators. , 1997, The American journal of cardiology.

[22]  J. Ansell,et al.  Evolving models of warfarin management: anticoagulation clinics, patient self-monitoring, and patient self-management. , 1996, American heart journal.

[23]  R B D'Agostino,et al.  Stroke severity in atrial fibrillation. The Framingham Study. , 1996, Stroke.

[24]  W. J. Hamilton,et al.  Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial , 1996, The Lancet.

[25]  D. Singer,et al.  An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. , 1996, The New England journal of medicine.

[26]  R B D'Agostino,et al.  Secular trends in the prevalence of atrial fibrillation: The Framingham Study. , 1996, American heart journal.

[27]  David C. Anderson,et al.  Differential effect of aspirin versus warfarin on clinical stroke types in patients with atrial fibrillation , 1996, Neurology.

[28]  L K Gottlieb,et al.  Anticoagulation in Atrial Fibrillation: Does Efficacy in Clinical Trials Translate Into Effectiveness in Practice? , 1994 .

[29]  E. Hylek,et al.  Risk Factors for Intracranial Hemorrhage in Outpatients Taking Warfarin , 1994, Annals of Internal Medicine.

[30]  Stroke Investigators.  Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study , 1994, The Lancet.

[31]  H. White,et al.  Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation : stroke prevention in atrial fibrillation II study. Commentary , 1994 .

[32]  Eaft Study Group.  Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke , 1993, The Lancet.

[33]  J. Rothrock,et al.  Ischemic stroke in patients with atrial fibrillation , 1993, Neurology.

[34]  Leandro Provinciali,et al.  Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke , 1993 .

[35]  J. Howard,et al.  Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. , 1993, The New England journal of medicine.

[36]  J. Slattery,et al.  Atrial fibrillation and stroke: prevalence in different types of stroke and influence on early and long term prognosis (Oxfordshire community stroke project) , 1992, BMJ.

[37]  D. Singer.  Randomized trials of warfarin for atrial fibrillation. , 1992, The New England journal of medicine.

[38]  S M Nazarian,et al.  Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. , 1992, The New England journal of medicine.

[39]  M Gent,et al.  Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. , 1991, Journal of the American College of Cardiology.

[40]  Lippincott Williams Wilkins,et al.  Stroke Prevention in Atrial Fibrillation Study: Final Results , 1991, Circulation.

[41]  Bernard Rosner,et al.  The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. , 1990, The New England journal of medicine.

[42]  Palle Petersen,et al.  PLACEBO-CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL FIBRILLATION The Copenhagen AFASAK Study , 1989, The Lancet.

[43]  R. Asinger,et al.  Cardiogenic brain embolism. The second report of the Cerebral Embolism Task Force. , 1989, Archives of neurology.

[44]  P. Wolf,et al.  Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. , 1987, Archives of internal medicine.